 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers...

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy...

Immuron Announces Positive Results Support Travelan  progress to Phase 3 Clinical Trials in the US

Gagnants
Le titre Ainos (NASDAQ:AIMD) a grimp jeudi de 101,78% 2,26 dollars lors de la session after-market.
Le titre Immuron (NASDAQ:IMRN) a grimp de 36,26% 6,20 dollars.
L'action Talis...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 07/03/2024

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...

Immuron Presentation Australian Biologics Festival 2024

Highlights: Travelan sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan YTD Jan 2024 sales $2.1 millionUSA Travelan YTD Jan 2024 sales $0.6...

Immuron achieves record Travelan  sales

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Highlights: Record half yearly Travelan sales of $2,334,969Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales51% higher than pre-pandemic period H1, FY20 sales...

Immuron achieves record half yearly Travelan  sales

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Volume (M)	26,247.00
52-Wk High	$5.96
52-Wk Low	$1.48

IMRN IMMURON Ltd/S ADR

About

Feed

News

Fundamentals